DRG Market Assessment reports

The breast cancer treatment landscape is rapidly evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) combined with endocrine therapy, are established…

Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…

Immune checkpoint inhibitors continue to anchor the treatment of non-small-cell lung cancer (NSCLC), while rapid advances in biomarker-driven strategies are accelerating patient segmentation and…

Clarivate Epidemiology’s coverage of endometrial carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts of key endometrial carcinoma patient populations, covering 171 countries and…

Clarivate Epidemiology’s coverage of endometrial cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with EGFR- and ALK-positive tumors generally receive…

China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…

Pancreatic cancer remains difficult to treat owing to the lack of treatment options—primarily surgery, radiation, and chemotherapy. Pancreatic adenocarcinoma represents the vast majority of…

The treatment landscape for small-cell lung cancer (SCLC) has seen significant advances in the past few years. Previously, chemotherapy and radiotherapy were the predominant treatments, but…

Clarivate Epidemiology’s coverage of liposarcoma comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…